An AI company just closed a $2.75 billion deal for drugs it designed itself
Insilico Medicine uses artificial intelligence to design new drugs. Pharmaceutical giant Eli Lilly is impressed enough to have signed a deal worth a potential $2.75 billion, making it one of the largest in the history of AI-driven drug development.
The deal between Insilico Medicine and Eli Lilly is not just big in financial terms. It marks a turning point: AI platforms that design drugs are no longer seen as clever toys for tech optimists, but as serious pipelines for the pharmaceutical industry. Insilico receives $115 million upfront, with the rest to be earned through milestones and royalties on sales. What Lilly is buying are licences to specific molecules from Insilico's portfolio, not software, but actual drug candidates designed by AI and subsequently tested in biological systems.
Insilico's approach combines generative AI, the same type of technology that powers ChatGPT, with specialised models capable of predicting and optimising molecular structures. The company has spent years working on drugs for age-related conditions, including fibrosis and cancer. One of its most talked-about candidates is a treatment for idiopathic pulmonary fibrosis, a fatal lung disease that affects almost exclusively older people. That candidate is already in clinical trials.
AI as drug designer: hype or breakthrough?
The promise of AI in drug development has long been that it makes the process cheaper and faster. Traditionally, bringing a single drug to market takes an average of ten to fifteen years and more than a billion dollars. Most candidates fail in clinical trials, often because they prove insufficiently effective or produce side effects that were invisible in the laboratory. AI models can, in theory, search the vast space of possible molecules far more quickly and pick out better candidates.
Whether that promise will be delivered on has not yet been proven. The real test is what happens in clinical trials with AI-designed molecules, and that data is still scarce. Insilico's fibrosis candidate is running, but results have not yet been published. The fact that Lilly is willing to strike such a large deal regardless suggests that confidence in the technology is growing, or that competitive pressure in the sector is so intense that nobody wants to risk being left behind.
What this means for longevity
For the broader field of aging research, this news matters for one specific reason: Insilico is explicitly focused on age-related diseases. If AI platforms can increase both the speed and the success rate of drug development in this space, they could compress the timeline to effective treatments. But between a landmark deal and an approved drug, there is always a long and uncertain road ahead.